KIPS News Alert Kips Bay Medical (KIPS) 0.2450 02/14/2015 01

New Post Public Reply Private Reply Replies (0) Message Board

Feb 14, 2015 at 2:42 AM

Kips Bay Medical (KIPS) 0.2450 $KIPS

Kips Bay Medical retrenches to focus on vein graft product
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 12:15PM CST

Kips Bay Medical Reorganizes Operations and Reduces Staff to Focus on Clinical Study Work and Conserve Capital
GlobeNewswire - Mon Jan 05, 11:00AM CST
Kips Bay Medical, Inc. (OTCQB:KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, eSVS Mesh, for use in coronary artery bypass grafting, or CABG, surgery, today announced that the Company has reorganized its operations by eliminating staff positions, instituting salary reductions and reducing its non-clinical related operating expenses, in order to conserve its capital while it pursues the completion of its current eMESH I clinical feasibility trial.

Kips Bay Medical Announces the First eSVS Mesh Implant by the Valley Hospital of New Jersey
GlobeNewswire - Tue Nov 11, 8:23AM CST
Manny Villafana, Chairman and CEO of Kips Bay Medical, Inc. (OTCQB:KIPS), announced that on November 4, 2014, cardiac surgeons at The Valley Hospital's Heart and Vascular Institute in Ridgewood, New Jersey, performed their first implant of an eSVS Mesh. This implant was performed as part of the Kips Bay Medical eMESH I clinical feasibility trial currently being conducted for the U.S. Food and Drug Administration (FDA) in a number of preeminent cardiac surgery centers in both Europe and the United States.

Kips Bay Medical Provides Feasibility Study Update and Reports Third Quarter 2014 Results
GlobeNewswire - Thu Nov 06, 8:45AM CST
Kips Bay Medical, Inc. (OTCQB:KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, eSVS Mesh, for use in coronary artery bypass grafting, or CABG, surgery, today provided a business update and announced financial results for its third quarter ended September 27, 2014.

Kips Bay Medical Q3 EPS of -$0.04
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 8:26AM CST

Kips Bay Medical Provides Clinical and Business Update
GlobeNewswire - Tue Oct 14, 8:00AM CDT
Kips Bay Medical, Inc. (OTCQB:KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, eSVS Mesh, for use in coronary artery bypass grafting, or CABG, surgery, today provides an update on its clinical progress and business operations.

Kips Bay Medical Announces Trading on OTCQB Marketplace
GlobeNewswire - Mon Sep 15, 9:05AM CDT
Kips Bay Medical, Inc. (OTCQB:KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, eSVS Mesh, for use in coronary artery bypass grafting, or CABG, surgery, today announced that its common stock began trading on the OTCQB Marketplace on September 12, 2014.

Kips Bay Medical Receives Updated CE Mark Approval
GlobeNewswire - Mon Aug 25, 8:00AM CDT
Kips Bay Medical, Inc. (Nasdaq:KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, eSVS Mesh, for use in coronary artery bypass grafting, or CABG, surgery, today announced that it has received an updated CE Mark approving use of a new surgical implant technique for its eSVS Mesh.

Kips Bay Medical Provides Feasibility Study Update and Reports Second Quarter 2014 Results
GlobeNewswire - Tue Aug 12, 8:05AM CDT
Kips Bay Medical, Inc. (Nasdaq:KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, eSVS Mesh, for use in coronary artery bypass grafting, or CABG, surgery, today provided a business update and announced financial results for its second quarter ended June 28, 2014.

Kips Bay Medical Announces the First eSVS Mesh Implant by Lenox Hill Hospital of New York
GlobeNewswire - Mon Jul 28, 8:03AM CDT
Manny Villafana, Chairman and CEO of Kips Bay Medical Inc. (Nasdaq:KIPS), announced that on July 17, 2014, Lenox Hill Hospital in New York City performed its first implant of an eSVS(R) Mesh. This implant was performed as part of the Kips Bay Medical eMESH I clinical feasibility trial currently being conducted for the U.S. Food and Drug Administration (FDA) in a number of preeminent cardiac surgery centers in both Europe and the United States.

Nasdaq stocks posting largest volume increases
AP - Thu Jul 03, 4:16PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
VITC: 7.99 (unch), LSBK: 13.50 (+0.24), VBFC: 17.00 (-0.81), ISLE: 10.09 (-0.24), CBAK: 2.80 (+0.03), SHIP: 0.75 (-0.02), IMCB: 20.00 (+0.31), CHNR: 1.91 (+0.01), VRTA: 2.73 (+0.01), ONFC: 13.15 (unch)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tomorrowland's Shanghai Return: An Electri-Lifesaver

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

ASTS Faces a Legal Countdown – Investors Take Note

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

AEVEX Faces 48-Hour Deadline for Investor Class Action

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Lundbeck's Board Leadership Transitions into New Era

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Faith and Resilience in China: The Legacy of the Long March

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Antheia Secures $80M for Critical Medicine Onshoring

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

UEG's New Advisory Board: Elevating Patient Voices

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...